The new salicylate derivative UR-1505 modulates the Th2/humoral response in a dextran sodium sulphate model of colitis that resembles ulcerative colitis.
Journal of pharmacological sciences • Vol. 109, Issue 2 • 2009
UR-1505, a salicylate able to selectively block T-cell activation, shows intestinal anti-inflammatory activity in the chronic phase of the DSS model of rat colitis.
Inflammatory bowel diseases • Vol. 14, Issue 7 • 2008
The intestinal anti-inflammatory effects of the novel agent UR-1505 in the TNBS model of rat colitis are mediated by T-lymphocyte inhibition.
Biochemical pharmacology • Vol. 74, Issue 10 • 2007
UR-1505, a new salicylate, blocks T cell activation through nuclear factor of activated T cells.
Molecular pharmacology • Vol. 72, Issue 2 • 2007